Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial.

Academic Article

Abstract

  • OBJECTIVE: Ovarian cancer screening with transvaginal ultrasound (TVU) and CA-125 was evaluated in the Prostate, Lung, Colorectal and Ovarian (PLCO) Trial. STUDY DESIGN: This was a randomized controlled trial of screening versus usual care. Baseline screening results are reported. RESULTS: Of 39,115 women randomized to receive screening, 28,816 received at least 1 test. Abnormal TVU was found in 1338 (4.7%), and abnormal CA-125 in 402 (1.4%). Twenty-nine neoplasms were identified (26 ovarian, 2 fallopian, and 1 primary peritoneal neoplasm). Nine were tumors of low malignant potential and 20 were invasive. The positive predictive value for invasive cancer was 3.7% for an abnormal CA-125, 1.0% for an abnormal TVU, and 23.5% if both tests were abnormal. CONCLUSION: The effect of screening on ovarian cancer mortality in the PLCO cohort has yet to be evaluated and will require longer follow-up. Screening identified both early- and late-stage neoplasms, and the predictive value of both tests was relatively low.
  • Keywords

  • Aged, CA-125 Antigen, Female, Humans, Mass Screening, Middle Aged, Ovarian Neoplasms, Predictive Value of Tests, Randomized Controlled Trials as Topic, Ultrasonography
  • Digital Object Identifier (doi)

    Author List

  • Buys SS; Partridge E; Greene MH; Prorok PC; Reding D; Riley TL; Hartge P; Fagerstrom RM; Ragard LR; Chia D
  • Start Page

  • 1630
  • End Page

  • 1639
  • Volume

  • 193
  • Issue

  • 5